StockData

iRhythm vs NovoCure

IRTC and NVCR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IRTC and NVCR compare

iRhythm is the larger company, worth 2.3 times as much as NovoCure ($3.0B against $1.3B).

iRhythm grew revenue faster over the last twelve months (25.6% versus 12.9% for NovoCure).

iRhythm keeps more of each dollar of sales as profit, with a net margin of −1.7% compared with −16.8% at NovoCure.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIRTCNVCR
Size and price
Market cap$3.0B$1.3B
Share price$89.67$11.14
Change, 1 year−47.5%−1.6%
Change, 5 years−8.5%−88.5%
Beta (5Y)1.391.23
Employees2,4001,605
StockData Score
Total score99
Valuation score12 (better)
Growth score4 (better)3
Performance score3 (better)1
Health score13 (better)
Dividend score00
Valuation
P/S3.6×1.8× (better)
P/B15.9×3.7× (better)
P/FCF75.8×–
FCF yield1.3% (better)−1.9%
Fair value$92.19$16.21
Margin of safety2.7%31.3% (better)
Growth
Revenue growth (TTM)25.6% (better)12.9%
Revenue growth, 5Y average23.0% (better)5.8%
Profitability
Gross margin71.5%77.0% (better)
Operating margin−3.0% (better)−17.2%
Net margin−1.7% (better)−16.8%
FCF margin4.7% (better)−3.4%
Return on equity−9.6% (better)−35.2%
Return on invested capital–−70.8%
Financial health
Debt / equity–0.07
Interest coverage−1.9×–
Current ratio3.85 (better)2.49
Altman Z-score2.20 (better)0.25
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–−0.28%
Shareholder yield0.00% (better)−0.28%
Ownership
Held by institutions108%88.5%
Held by insiders2.1%3.0%
Insider net buying, 12 months−$24.4M−$3.4M (better)
Short interest, % of float10.1%11.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.